Overview

A Phase II Study in Patients With Alopecia Areata

Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
0
Participant gender:
All
Summary
This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Reistone Biopharma Company Limited
Criteria
Inclusion Criteria:

- Male or female subjects between 18-65 years of age (both inclusive), at the time of
informed consent;

- Must have moderate to severe alopecia areata.

Exclusion Criteria:

- Other types of alopecia or other diseases that can cause hair loss

- Other scalp diseases that could interfere with assessment of hair loss/regrowth

- Any previous use of any Janus kinase (JAK) inhibitor